

Authors



Professor Neil R Poulter

Professor of Preventive Cardiovascular Medicine
International Centre for Circulatory Health
Imperial College London, UK



Professor Peter Sever

Professor of Clinical Pharmacology and Therapeutics
International Centre for Circulatory Health
Imperial College London, UK

Contributing authors

Professor Björn Dahlöf

Associate Professor of Medicine
Sahlgrenska University Hospital/Östra
Gothenburg, Sweden

Professor Hans Wedel

Professor of Epidemiology and Biostatistics
Nordic School of Public Health
Gothenburg, Sweden

ORDER NOW AND SAVE 10%

Recommended retail price **£14.99 €23.00**

Special offer price **£13.50 €20.50**

Name:

Address:

.....

Postcode:

Tel: Email:

Copies @ £13.50 / €20.50 each plus postage & packaging @ £1.50 / €2.20 per book. Cheques payable to: Sherborne Gibbs Limited. Credit cards accepted, please provide details below.

Card No.:

Expiry date: 3-digit security number:

Signature:

Please complete the above form and return with payment to:

Mrs Jane Boyle, Sherborne Gibbs Limited

Edgbaston House, 3 Duchess Place, Edgbaston, Birmingham B16 8NH, UK

Tel: +44 (0)121 454 4114 • Fax: +44 (0)121 454 1190 • email: jboyle@sherborgegibbs.co.uk

Published by **SHERBORNE / GIBBS / LIMITED**

SPECIAL OFFER - SAVE 10%

Anglo-Scandinavian
ascot
Cardiac Outcomes Trial

Second edition

Anglo-Scandinavian Cardiac Outcomes Trial

History, results and implications
for clinical practice

Neil R Poulter
Peter Sever

Björn Dahlöf
Hans Wedel


UPDATED & EXPANDED
SECOND EDITION

The results and implications of a landmark study

The final results of the unique Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT) are published and presented.

ASCOT is the largest study of hypertension ever undertaken in Europe involving >19,000 patients and also includes the study of lipid management in >10,000 patients.

The results of ASCOT have had a significant impact on the prevention of coronary heart disease (CHD) and other vascular events by lowering blood pressure and reducing cholesterol.



It provides the healthcare professional with critically important new insights into:

- The comparative efficacy of specific combinations of antihypertensive drugs.
- The value of reducing CHD risk by achieving control of blood pressure and effective lowering of cholesterol.

This book provides clinicians with a comprehensive and detailed review of the final results of ASCOT and some further analyses of the trial data.

Additionally, the authors discuss implications of ASCOT for daily practice.

Contents

- 1 The history of ASCOT
- 2 Why treat blood pressure?
- 3 Hypertension trial review – ASCOT in context
- 4 Design, conduct and methods
- 5 ASCOT electronic data capture
- 6 ASCOT main results and implications:
 - LLA
 - BPLA
- 7 The principal results of the Conduit Artery Function Evaluation (CAFE) study in ASCOT
- 8 Treating and preventing type 2 diabetes in ASCOT-BPLA
- 9 A patient's experience of ASCOT
- 10 Reflections and next steps
- 11 ASCOT Committees and Investigations

>100 figures and tables